| Synonyms: | |
| Status: | Approved (1995) |
| Entry Type: | Small molecule |
| Molecule Category: | Parent |
| ATC: | C09CA01 |
| UNII: | JMS50MPO89 |
| InChI Key | PSIFNNKUMBGKDQ-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C22H23ClN6O |
| Molecular Weight | 422.92 |
| AlogP | 4.27 |
| Hydrogen Bond Acceptor | 6.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 8.0 |
| Polar Surface Area | 92.51 |
| Molecular species | ACID |
| Aromatic Rings | 4.0 |
| Heavy Atoms | 30.0 |
| Primary Target | |
|---|---|
| AT1 receptor |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Diabetic Nephropathies | 3 | D003928 | ClinicalTrials |
| Glioblastoma | 3 | D005909 | ClinicalTrials |
| Hypertension | 3 | D006973 | ClinicalTrials |
| Severe Acute Respiratory Syndrome | 3 | D045169 | ClinicalTrials |
| Kidney Diseases | 3 | D007674 | ClinicalTrials |
| Heart Failure | 3 | D006333 | ClinicalTrials |
| Renal Insufficiency, Chronic | 3 | D051436 | ClinicalTrials |
| Glomerulonephritis, IGA | 3 | D005922 | ClinicalTrials |
| Non-alcoholic Fatty Liver Disease | 3 | D065626 | ClinicalTrials |
| Essential Hypertension | 3 | D000075222 | ClinicalTrials |
| Proteinuria | 3 | D011507 | ClinicalTrials |
| Hyperoxaluria, Primary | 3 | D006960 | ClinicalTrials |
| Marfan Syndrome | 3 | D008382 | ClinicalTrials |
| Severe Acute Respiratory Syndrome | 3 | D045169 | ClinicalTrials |
| Hypertension, Pulmonary | 3 | D006976 | ClinicalTrials |
| Hypertrophy, Left Ventricular | 3 | D017379 | ClinicalTrials |
| Diabetes Mellitus, Type 1 | 2 | D003922 | ClinicalTrials |
| Pancreatic Neoplasms | 2 | D010190 | ClinicalTrials |
| Sarcopenia | 2 | D055948 | ClinicalTrials |
| Respiratory Distress Syndrome | 2 | D012128 | ClinicalTrials |
| Cystic Fibrosis | 2 | D003550 | ClinicalTrials |
| Inflammation | 2 | D007249 | ClinicalTrials |
| Glomerulosclerosis, Focal Segmental | 2 | D005923 | ClinicalTrials |
| Anemia, Sickle Cell | 2 | D000755 | ClinicalTrials |
| Cardiomyopathy, Hypertrophic | 2 | D002312 | ClinicalTrials |
| HIV Infections | 2 | D015658 | ClinicalTrials |
| Idiopathic Pulmonary Fibrosis | 2 | D054990 | ClinicalTrials |
| Stress Disorders, Post-Traumatic | 2 | D013313 | ClinicalTrials |
| Constriction, Pathologic | 1 | D003251 | ClinicalTrials |
| Melanoma | 1 | D008545 | ClinicalTrials |
| Aging | 1 | D000375 | ClinicalTrials |
| Wounds and Injuries | 1 | D014947 | ClinicalTrials |
| Osteoarthritis, Knee | 1 | D020370 | ClinicalTrials |
| Diabetes Mellitus, Type 2 | 1 | D003924 | ClinicalTrials |
| Osteosarcoma | 1 | D012516 | ClinicalTrials |
| Peripheral Arterial Disease | 0 | D058729 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 114798-26-4 |
| ChEBI | 6541 |
| ChEMBL | CHEMBL191 |
| DrugBank | DB00678 |
| DrugCentral | 1610 |
| EPA CompTox | DTXSID7023227 |
| FDA SRS | JMS50MPO89 |
| Human Metabolome Database | HMDB0014816 |
| Guide to Pharmacology | 590 |
| KEGG | C07072 |
| PDB | LSN |
| PharmGKB | PA450268 |
| PubChem | 3961 |
| SureChEMBL | SCHEMBL60 |
| ZINC | ZINC000003873160 |